Giant Cell Arteritis: Examining Challenges in Diagnosis and Treatment
Improved biomarkers are needed to monitor disease activity effectively in giant cell arteritis.
Improved Immune Response to Pneumococcal Vaccine in ANCA-Associated Vasculitis
Suppressing cytomegalovirus may improve the immune response to a T cell-dependent pneumococcal vaccination in patients experiencing ANCA-associated vasculitis.
Granulomatosis With Polyangiitis Linked to Altered Nasal Microbial Composition
Granulomatosis with polyangiitis was associated with an altered nasal microbial composition at both the bacterial and the fungal levels.
Examining Risk for Severe Infection in Rituximab-Treated AAV
Researchers observed severe infections in one-quarter of patients with AAV receiving rituximab.
Renal Transplantation Linked to Improved Survival for ESRD Due to Granulomatosis With Polyangiitis
Renal transplantation is associated with a significant decrease in mortality among patients with end-stage renal disease attributed to granulomatosis with polyangiitis.
Individually Tailored vs Fixed-Schedule Rituximab Regimens in ANCA-Associated Vasculitis
Results of the MAINRITSAN2 trial show that ANCA-associated vasculitides relapse rates did not differ significantly among patients treated with individually tailored vs fixed-schedule rituximab infusion regimens.
Takayasu Arteritis: Efficacy and Safety of Tocilizumab vs Placebo
Tocilizumab therapy improves time to relapse in Takayasu arteritis with a favorable safety and tolerability profile.
Large Vessel Vasculitis Imaging: Recommendations for Clinical Practice
EULAR has released 12 evidence-based recommendations for the use of imaging in the diagnosis and monitoring of large vessel vasculitis, including giant cell arteritis and Takayasu arteritis.
First Treatment for Eosinophilic Granulomatosis With Polyangiitis Approved by FDA
The FDA has expanded the approval of mepolizumab for treating eosinophilic granulomatosis with polyangiitis, which causes vasculitis.
Azathioprine With Glucocorticoids in Nonsevere Systemic Necrotizing Vasculitides
Adding azathioprine to glucocorticoids has no significant benefit for patients with nonsevere systemic necrotizing vasculitides.
Rheumatology Advisor Articles
- Ustekinumab Effective in Phase 2 Study for Systemic Lupus Erythematosus
- Manufacturers Increase Drug Prices Twice as Fast During Drug Shortages
- Ultrasound Can Reveal Renal Medulla Urate Deposits in Tophaceous Gout
- Depression Prevalent Among Individuals With Systemic Sclerosis
- TNF-α Inhibitor Therapy May Benefit Extracellular Matrix Remodeling in Women With RA
- Effects of Statin Use on Pain Outcomes in Knee Osteoarthritis
- MicroRNAs Linked to Increased Cortical Bone Porosity in Postmenopausal Women With History of Fracture
- Giant Cell Arteritis: Examining Challenges in Diagnosis and Treatment
- Manufacturers Increase Drug Prices Twice as Fast During Drug Shortages
- Identifying Warning Signs of Depression in a Fellow Clinician